Upcoming Event: Vaccine World Summit India 2013
11/8/2012
Event: Vaccine World Summit India 2013
Dates: March 5 - 7, 2013
Venue: Pune, India
Contact: Patricia Chong
Tel: +65 6493 1871
Third Vaccine World Summit gathers industrial thought leaders to strength R&D capacity in India through strategic partnerships
The Indian vaccine industry, valued at US$350 million in 2011, is expected to significantly expand, reaching the size of US $871million by 2016. As the global vaccine industry landscape shift towards India, the Indian government sees the need to make unprecedented changes to the growing industry. In 2009, the Indian government has declared 2010-2020 as the "Decade of Innovations", promoting innovations in the health care sector through various schemes.
As India shift from being a low cost generic vaccine suppliers into R&D power house, local vaccine manufacturers seek to fast track and gain greater access to the latest vaccine technologies through global partnerships. In the recent years, there is a significant rise in global partnerships where international and local vaccine players come together to learn and complement one another's capabilities.
Upon the launch of the first Japanese Encephalitis vaccine in India, a collaborative effort, manufactured by Biological E based on Interncell's technology, Thomas Linngelbach, CEO of Intercell commented that the strategic partnership is vital in this remarkable success. Dr Modi, Chairman of Cadila Pharmaceuticals also attributed the exceptionally speedy progress of their new vaccine development to their Joint Venture with Novavax, while Stanley Erck, President and CEO of Novavax trust that the collaboration will expand Novavax's vaccine development capability and add to their global manufacturing capacity.
Into its 3rd year of running, Vaccine World Summit India continues to provide an unrivaled meeting platform in India from March 5 - 7 2013 for leading vaccine industry players to explore partnership opportunities at various stages of the vaccine lifecycle, from the earliest basic research, extends through licensure to all dimensions of the vaccine production.